| pubmed-article:1978946 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:1978946 | lifeskim:mentions | umls-concept:C0007095 | lld:lifeskim |
| pubmed-article:1978946 | lifeskim:mentions | umls-concept:C0037659 | lld:lifeskim |
| pubmed-article:1978946 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:1978946 | lifeskim:mentions | umls-concept:C0427574 | lld:lifeskim |
| pubmed-article:1978946 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:1978946 | pubmed:dateCreated | 1991-1-8 | lld:pubmed |
| pubmed-article:1978946 | pubmed:abstractText | One of the major manifestations of the carcinoid syndrome is secretory diarrhea thought to be due to overproduction of 5-hydroxytryptamine (5-HT). Synthetic somatostatin analogues have proved to be clinically effective in controlling this diarrhea. We have established a continuous cell line from a human pancreatic carcinoid tumor that secretes 5-HT. We examined the ability of the somatostatin analogue, SMS 201-995, to inhibit 5-HT release in vitro. Tumor cells were exposed to SMS 201-995 (10(-6) mol/L), pentagastrin (10(-9) mol/L), acetylcholine (10(-5) mol/L), and isoproterenol (10(-5) mol/L) alone and in combination; 5-HT release was assayed with high pressure liquid chromatography. We found that pentagastrin (6.43 +/- 0.64 ng/ml), isoproterenol (20.24 +/- 2.17 ng/ml), and acetylcholine (12.39 +/- 1.10 ng/ml) each stimulated release of 5-HT compared to control values (4.38 +/- 0.42 ng/ml). SMS 201-995 significantly reduced release of 5-HT in response to isoproterenol and acetylcholine but did not inhibit the effect of pentagastin. These data suggest that different agents do not act through the same pathway to stimulate 5-HT release from human pancreatic carcinoid cells. | lld:pubmed |
| pubmed-article:1978946 | pubmed:language | eng | lld:pubmed |
| pubmed-article:1978946 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1978946 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:1978946 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1978946 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1978946 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1978946 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1978946 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1978946 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1978946 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:1978946 | pubmed:month | Dec | lld:pubmed |
| pubmed-article:1978946 | pubmed:issn | 0039-6060 | lld:pubmed |
| pubmed-article:1978946 | pubmed:author | pubmed-author:ThompsonJ CJC | lld:pubmed |
| pubmed-article:1978946 | pubmed:author | pubmed-author:HaberBB | lld:pubmed |
| pubmed-article:1978946 | pubmed:author | pubmed-author:TownsendC... | lld:pubmed |
| pubmed-article:1978946 | pubmed:author | pubmed-author:IshizukaJJ | lld:pubmed |
| pubmed-article:1978946 | pubmed:author | pubmed-author:LawrenceJ PJP | lld:pubmed |
| pubmed-article:1978946 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:1978946 | pubmed:volume | 108 | lld:pubmed |
| pubmed-article:1978946 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:1978946 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:1978946 | pubmed:pagination | 1131-4; discussion 1134-5 | lld:pubmed |
| pubmed-article:1978946 | pubmed:dateRevised | 2004-11-17 | lld:pubmed |
| pubmed-article:1978946 | pubmed:meshHeading | pubmed-meshheading:1978946-... | lld:pubmed |
| pubmed-article:1978946 | pubmed:meshHeading | pubmed-meshheading:1978946-... | lld:pubmed |
| pubmed-article:1978946 | pubmed:meshHeading | pubmed-meshheading:1978946-... | lld:pubmed |
| pubmed-article:1978946 | pubmed:meshHeading | pubmed-meshheading:1978946-... | lld:pubmed |
| pubmed-article:1978946 | pubmed:meshHeading | pubmed-meshheading:1978946-... | lld:pubmed |
| pubmed-article:1978946 | pubmed:meshHeading | pubmed-meshheading:1978946-... | lld:pubmed |
| pubmed-article:1978946 | pubmed:meshHeading | pubmed-meshheading:1978946-... | lld:pubmed |
| pubmed-article:1978946 | pubmed:meshHeading | pubmed-meshheading:1978946-... | lld:pubmed |
| pubmed-article:1978946 | pubmed:meshHeading | pubmed-meshheading:1978946-... | lld:pubmed |
| pubmed-article:1978946 | pubmed:meshHeading | pubmed-meshheading:1978946-... | lld:pubmed |
| pubmed-article:1978946 | pubmed:year | 1990 | lld:pubmed |
| pubmed-article:1978946 | pubmed:articleTitle | The effect of somatostatin on 5-hydroxytryptamine release from a carcinoid tumor. | lld:pubmed |
| pubmed-article:1978946 | pubmed:affiliation | Department of Surgery, University of Texas Medical Branch, Galveston 77550. | lld:pubmed |
| pubmed-article:1978946 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1978946 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1978946 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1978946 | lld:pubmed |
